Pcas: Q1 2021 Net Sales
Ecully, France – April 21, 2021
Q1 2021 NET SALES
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as at March 31, 2021.
The PCAS Group had generated consolidated net
sales of €51.8 million as of March 31, 2021, representing a
decrease of 2.8% compared to the same period of the previous
financial year (-0.8% at a constant exchange rate).
In millions of euros |
|
2021 |
|
2020 |
|
% change |
|
2021 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Sales
as of 31 March |
|
51.8 |
|
53.3 |
|
-2.8% |
|
52.9 |
|
-0.8% |
Pharmaceutical
Synthesis |
|
35.3 |
|
36.2 |
|
-2.6% |
|
36.2 |
|
0.0% |
Fine Specialty Chemicals |
|
16.5 |
|
17.1 |
|
-3.3% |
|
16.7 |
|
-2.5% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated sales of €35.3 million, down 2.6% on 2020 (stable at a
constant exchange rate). R&D activity was up sharply in the
first quarter (+60%), confirming the recovery expected following
the slowdown in clinical trials during the health crisis in 2020.
On the other hand, efforts made in response to the Covid-19 health
emergency, in particular the production of hand sanitizer sold
under the Naaha brand, had generated significant sales in the first
quarter of 2020 which were not repeated on the same scale in the
first quarter of 2021. This first quarter of 2021 also marked the
launch of sales of Estetrol to Mithra. Estetrol is produced in the
new highly potent pharmaceutical drug production workshop at the
Villeneuve-la-Garenne site, which was inaugurated in September
2020.
Fine Specialty Chemicals
Sales of fine specialty chemicals amounted to
€16.5 million, down 3.3% compared to 2020 (-2.5% at a constant
exchange rates). The Electronics business confirmed the strong
performance seen in 2020, with double-digit growth in the first
quarter. However, lubricants and fine chemicals activities have not
yet returned to pre-crisis levels, despite a positive trend in
lubricants.
Governance
Mrs Pauline Ginestié and Mr Alain de Salaberry
resigned from their directorships on April 19 and April 10, 2021
respectively. On April 21, 2021, the Board of Directors takes note
of the non-renewal of Marc de Roquefeuil's term of office, which
expires at the next Shareholder’s Meeting on June 9, 2021. At the
end of this Shareholder’s Meeting, the Board of Directors will
therefore be composed as follows:
- Pierre Luzeau
(Chairman)
- Vincent
Milhau
- Vanessa
Michoud
- Jacqueline
Lecourtier (independent director)
The Board of Directors thereby will consider in
the coming months the possibility to propose one or more
independent directors to be appointed by the Shareholder’s
Meeting.
Outlook
As mentioned in our previous press releases
since end-March 2020, the global health crisis relating to the
coronavirus is changing by the day, and there is still a gray area
surrounding its duration, its extent and its effects on companies'
production lines and consumption in general.
The potential impacts in the medium term remain
difficult to anticipate. This crisis still calls for cautious
measures. Due to the exceptional circumstances, the Group has
suspended its financial targets and its strategic business
objectives until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE:
2020 Shareholder’s Meeting, June 9, 2021, at 10
a.m
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €194.1 million in 2020 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor
relation |
Tél. : +33 1 69 79 60 00www.pcas.com |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
|
|
- PCAS - Communiqué de presse - Chiffre d'affaires au 31 mars
2021 - US_DEF
PCAS (EU:PCA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
PCAS (EU:PCA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024